Watson Pharmaceuticals said that the launch was a part of a settlement agreement with Novartis Pharmaceuticals, Novartis Pharma, Novartis AG, Novartis International, and Proterra (collectively Novartis).
Exelon is used to treat dementia in people suffering with Alzheimer’s disease. Exelon is known to improve the function of nerve cells in the brain. It works by preventing the breakdown of a chemical called acetylcholine.
As per the terms of the agreement between Watson and Novartis in December 6, 2007, Watson has received license to Novartis’ US patents covering Exelon for a generic version of Exelon.
Watson received approval from FDA on January 8, 2008, for its abbreviated new drug application of generic version of Exelon.